Glenolden Shoprite Pharmacy Pharmacy Location: 140 N Macdade Blvd, Glenolden, Pennsylvania 19036 Phone: (610) 461-1746 |
Cvs Pharmacy # 00675 Durable Medical Equipment & Medical Supplies Location: 159 N Macdade Blvd, Glenolden, Pennsylvania 19036 Phone: (610) 522-0600 |
Rite Aid Pharmacy 01566 Durable Medical Equipment & Medical Supplies Location: 327 N Chester Pike, Glenolden, Pennsylvania 19036 Phone: (610) 583-8600 |
Wal-mart Pharmacy 10-5495 Durable Medical Equipment & Medical Supplies Location: 50 N Macdade Blvd, Glenolden, Pennsylvania 19036 Phone: (610) 583-2206 |
Walgreens #4429 Durable Medical Equipment & Medical Supplies Location: 150 N Macdade Blvd, Glenolden, Pennsylvania 19036 Phone: (610) 586-5224 |
News Archive
The Department of Justice on Monday joined a whistleblower lawsuit filed against California-based Dey, a generic medication division of Germany-based Merck KGaA, over allegations that the company inflated prices reported to federal health insurance programs, the Boston Globe reports.
On June 15, the Lymphoma Research Foundation (LRF), in collaboration with the John Theurer Cancer Center at Hackensack University Medical Center, will bring together lymphoma experts to discuss the latest practices in the diagnosis and management of lymphoma.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
ThromboGenics NV and BioInvent International AB today announced positive results from a Phase I trial of their novel anti-cancer monoclonal antibody TB-403 in patients with advanced solid tumours. The results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, U.S. TB-403 was well tolerated with no reported dose limiting toxicity. These positive data support progression of TB-403 and further development.
› Verified 7 days ago